Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Gareth Veal.

Newcastle AuthorsTitleYearFull text
Dr Shelby Barnett
Dr Vickyanne Carruthers
Professor Deborah Tweddle
Professor Gareth Veal
Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance2022
Dr Vickyanne Carruthers
Dr Shelby Barnett
Dr Tasnim Arif
Professor Gareth Veal
Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series2022
Dr Shelby Barnett
Professor Gareth Veal
Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations2022
Professor Gareth Veal
Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)2022
Dr Shelby Barnett
Professor Deborah Tweddle
Professor Gareth Veal
Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients2022
Melanie Griffin
Dr Claire Jennings
Professor Gareth Veal
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia2021
Dr Catherine Gowland
Philip Berry
Julie Errington
Professor Gareth Veal
Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study2021
Dr Shelby Barnett
Professor Gareth Veal
Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom2021
Dr Shelby Barnett
Julie Errington
Julieann Sludden
Dr David Jamieson
Professor Gareth Veal
et al.
Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population2021
Professor Gareth Veal
Professor Deborah Tweddle
Julie Errington
Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trial2021
Eve Roberts
Dr Jasper Mogg
Professor Gareth Veal
Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective2020
Dr Karen Barker
Philip Berry
Professor Gareth Veal
Dr John Anderson
In vivo Modelling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis2019
Suriyon Uitrakul
Dr Claire Hutton
Professor Gareth Veal
Dr David Jamieson
A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells2019
Dr Marina Danilenko
Dr Kirsty Hodgson
Monique Zangarini
Professor Gareth Veal
Dr Neil Rajan
et al.
Diverse assays from a single skin punch biopsy to assess topical drug intervention2019
Professor Gareth Veal
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function2019
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.
Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Dr Rosanna Jackson
Philip Berry
Julie Errington
Professor Julie Irving
Professor Gareth Veal
et al.
Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial2019
Professor Gareth Veal
Philip Berry
Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste2019
Professor Gareth Veal
Dr Edward Amankwatia
Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities2019
Professor Gareth Veal
Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition2019
Professor Gareth Veal
Julie Errington
Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function2019
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Calum Kirk
Dr Katrina Wood
et al.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma2019
Professor Gareth Veal
Julie Errington
Dr Leigh McDonald
Professor Deborah Tweddle
The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression2019
Professor Ruth Plummer
Professor Steve Wedge
Professor Gareth Veal
A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours2018
Professor Gareth Veal
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence2018
Professor Gareth Veal
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss2018
Dr Marina Danilenko
Elaine Stamp
Dr Deborah Stocken
Monique Zangarini
Amy Cranston
et al.
Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib2018
Monique Zangarini
Philip Berry
Professor Gareth Veal
Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts2018
Dr Lynsey McKenzie
Hasan Issa
Sandeep Potluri
Dr Helen Blair
Asmida Isa
et al.
The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation2018
Professor Gareth Veal
The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients2018
Professor Gareth Veal
Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report2018
Dr Britta Vormoor
Professor Gareth Veal
Melanie Griffin
Professor Julie Irving
Lynne Minto
et al.
A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia2017
Monique Zangarini
Philip Berry
Julieann Sludden
Professor Gareth Veal
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma2017
Monique Zangarini
Dr Neil Rajan
Dr Marina Danilenko
Philip Berry
Professor Gareth Veal
et al.
Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors2017
Professor Gareth Veal
Dr David Jamieson
Katja Kuver
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial2017
Dr Lindi Chen
Philip Berry
Dr Jennifer Bonner
Dr Katrina Wood
Professor Gareth Veal
et al.
In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma2017
Professor Gareth Veal
Carine Boue
Charlotte Lecour
Annette Otto
Maryam Rastegari
et al.
Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey2017
Professor Gareth Veal
Julie Errington
Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens2016
Professor Gareth Veal
Julieann Sludden
Dr David Jamieson
Julie Errington
Dr Ghada Malik
et al.
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma2016
Chris Walsh
Dr Jennifer Bonner
Professor Alan Boddy
Professor Gareth Veal
Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer2016
Julie Errington
Dr Ghada Malik
Lisa Price
Professor Gareth Veal
Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK2016
Rosanna Jackson
Professor Julie Irving
Professor Gareth Veal
Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia2016
Professor Gareth Veal
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-22016
Dr Vikram Gota
Professor Gareth Veal
Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients.2016
Professor Gareth Veal
Julie Errington
Dr James Hayden
Professor Deborah Tweddle
Carboplatin therapeutic monitoring in preterm and full-term neonates2015
Professor Gareth Veal
Julie Errington
Dr James Hayden
Professor Deborah Tweddle
Carboplatin therapeutic monitoring in preterm and full-term neonates2015
Professor Gareth Veal
Julie Errington
Professor Deborah Tweddle
Therapeutic drug monitoring approaches to the treatment of preterm and full-term neonates with cancer - A UK experience2015
Professor Gareth Veal
Blood volumes in paediatric clinical trials: a review of current regulations and guidance for research studies2014
Dr Chris Hill
Julie Errington
Dr Ghada Malik
Professor Alan Boddy
Professor Gareth Veal
et al.
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer2014
Professor Gareth Veal
Dr Pamela Kearns
Defining a Target Intra-Cerebrospinal Fluid Steady State Etoposide Concentration [CSF Etoposide) for Phase I Study in Children with Leptomeningeal Metastasis (LM): Intrepid, A First in Man Study2014
Professor Gareth Veal
Dr David Walker
Etoposide Pharmacokinetics Following Intra-Cerebrospinal Fluid Administation in Patients with Leptomeningeal Metastases2014
Professor Gareth Veal
Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib2014
Professor Gareth Veal
Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics2014
Professor Gareth Veal
Review of therapeutic drug monitoring of anticancer drugs part 2 – Targeted therapies2014
Professor Gareth Veal
Therapeutic drug monitoring in cancer – Are we missing a trick?2014
Professor Gareth Veal
Julie Errington
Sophie Rowbotham
Nicola Illingworth
Dr Ghada Malik
et al.
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma2013
Christopher Hill
Dr David Jamieson
Huw Thomas
Dr Colin Brown
Professor Alan Boddy
et al.
Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo2013
Professor Gareth Veal
Julie Errington
Dr Ghada Malik
Dr Chris Hill
Professor Alan Boddy
et al.
Investigating the pharmacokinetics and dosing of anticancer drugs in infants and young children2013
Professor Gareth Veal
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial2012
Professor Gareth Veal
Professor Alan Boddy
Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring2012
Professor Gareth Veal
Professor Alan Boddy
Chemotherapy in newborns and preterm babies2012
Professor Isabella Orienti
Professor Gareth Veal
Novel micelles based on amphiphilic branched PEG as carriers for fenretinide2012
Dr Caroline Bridgens
Professor Gareth Veal
Dr Chris Redfern
Dr Jane Renwick
Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold2012
Professor Ann Daly
Professor Gareth Veal
Dr David Jamieson
Dr Sally Coulthard
Pharmacogenomics research at Newcastle University2012
Dr Caroline Bridgens
Professor Gareth Veal
Dr Chris Redfern
Dr Jane Renwick
Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates2012
Dr Jane Renwick
Shaun Martin
Nicola Illingworth
Dr David Jamieson
Professor Penny Lovat
et al.
The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide2012
Dr Emma Meczes
Huw Thomas
Professor Richard Edmondson
Professor Gareth Veal
Professor Alan Boddy
et al.
Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours2012
Professor Alan Boddy
Professor Ann Daly
Professor Gareth Veal
Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases2011
Julie Errington
Professor Alan Boddy
Professor Gareth Veal
Mike Cole
Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy2011
Julie Errington
Professor Alan Boddy
Professor Gareth Veal
Mike Cole
Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients2011
Dr Caroline Bridgens
Professor Gareth Veal
Dr Chris Redfern
Dr Jane Renwick
Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates2011
Dr Caroline Bridgens
Professor Gareth Veal
Dr Chris Redfern
Dr Jane Renwick
Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26)2011
Professor Gareth Veal
Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines2010
Professor Gareth Veal
Clinical pharmacology in the adolescent oncology patient2010
Mike Cole
Professor Alan Boddy
Professor Gareth Veal
Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate2010
Bertrand Girard
Professor Gareth Veal
Oxazaphosphorines: New therapeutic strategies for an old class of drugs2010
Professor Gareth Veal
Julie Errington
Professor Andrew Pearson
Professor Alan Boddy
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients2010
Dr Jane Renwick
Dr Ross Flockhart
Professor Gareth Veal
Professor Penny Lovat
Dr Chris Redfern
et al.
Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells2010
Sophie Rowbotham
Professor Alan Boddy
Dr Chris Redfern
Professor Gareth Veal
Professor Ann Daly
et al.
Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation2010
Sophie Rowbotham
Professor Ann Daly
Professor Gareth Veal
Professor Alan Boddy
Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans2010
Dr Malcolm Coulthard
Dr Bridget Wilkins
Mike Cole
Professor Gareth Veal
Dr Michael Keir
et al.
Human renal function maturation: a quantitative description using weight and postmenstrual age2009
Julie Errington
Professor Alan Boddy
Professor Gareth Veal
Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma2009
Mike Cole
Professor Alan Boddy
Dr Michael Keir
Professor Gareth Veal
Estimation of renal function and its potential impact on carboplatin dosing in children with cancer2008
Dr Jane Renwick
Professor Gareth Veal
Dr Chris Redfern
Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells2008
Professor Gareth Veal
Professor Alan Boddy
Population pharmacokinetic investigation of actinomycin D in children and young adults2008
Mike Cole
Annie Parry
Dr Michael Reid
Professor Alan Boddy
Professor Gareth Veal
et al.
A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer2007
Professor Gareth Veal
Julie Errington
Dr Michael Tilby
Professor Alan Boddy
Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours2007
Professor Alan Boddy
Melanie Griffin
Julie Errington
Professor Gareth Veal
Dosing of cancer patients with low or absent renal function2007
Dr Michael Keir
Mike Cole
Annie Parry
Professor Alan Boddy
Professor Gareth Veal
et al.
Estimating glomerular filtration rate in children with cancer - Impact of methodology on carboplatin dosing2007
Dr Jane Renwick
Gordon Taylor
Huw Thomas
Professor Alan Boddy
Dr Chris Redfern
et al.
Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo2007
Professor Gareth Veal
Mike Cole
Geoffrey Taylor
Julie Errington
Professor Alan Boddy
et al.
Pharmacogenetics and metabolism of cyclophosphamide in paediatric cancer patients2007
Professor Gareth Veal
Mike Cole
Julie Errington
Professor Alan Boddy
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group2007
Professor Gareth Veal
Sophie Rowbotham
Professor Alan Boddy
Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma2007
Dr Jane Renwick
Professor Gareth Veal
Dr Chris Redfern
Professor Penny Lovat
Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours2007
Professor Gareth Veal
Julie Errington
Huw Thomas
Professor Alan Boddy
Biliary excretion of etoposide in children with cancer2006
Professor Gareth Veal
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B112006
Mike Cole
Professor Alan Boddy
Dr Pamela Kearns
Lisa Price
Annie Parry
et al.
Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?2006
Dr Jane Renwick
Dr Chris Redfern
Professor Gareth Veal
13-cis Retinoic acid and isomerisation in paediatric oncology - Is changing shape the key to success?2005
Dr Jane Renwick
Professor Alan Boddy
Dr Chris Redfern
Professor Andrew Pearson
Professor Gareth Veal
et al.
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells2005
Professor Gareth Veal
Mike Cole
Julie Errington
Annie Parry
Dr Juliet Hale
et al.
Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study2005
Professor Gareth Veal
Dr Michael Tilby
A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia2004
Mike Cole
Annie Parry
Dr Michael Keir
Professor Andrew Pearson
Professor Alan Boddy
et al.
Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics2004
Professor Gareth Veal
Professor Alan Boddy
Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy2004
Professor Gareth Veal
Dr Sally Coulthard
Professor Alan Boddy
Chemotherapy individualization2003
Professor Gareth Veal
Clinical and cellular pharmacology in relation to solid tumours of childhood2003
Professor Gareth Veal
Julie Errington
Julieann Sludden
Melanie Griffin
Annie Parry
et al.
Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
Julie Errington
Professor Gareth Veal
Julieann Sludden
Melanie Griffin
Professor Andrew Pearson
et al.
Determination of the anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry2003
Justin Armstrong
Professor Gareth Veal
Dr Chris Redfern
Professor Alan Boddy
Effects of ketoconazole and acitretin on retinoid isomerisation and metabolism in neuroblastoma2003
Professor Gareth Veal
Julie Errington
Professor Andrew Pearson
Professor Alan Boddy
Poster Presentation: Oxidative metabolism of 13-cis-retinoic acid in children with neuroblastoma2003
Dr Birju Rana
Professor Gareth Veal
Professor Andrew Pearson
Dr Chris Redfern

Retinoid X receptors and retinoid response in neuroblastoma cells

2002
Professor Gareth Veal
Julie Errington
Dr Chris Redfern
Professor Andrew Pearson
Professor Alan Boddy
et al.
Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells2002
Dr Birju Rana
Professor Gareth Veal
Professor Andrew Pearson
Dr Chris Redfern
Retinoid X receptors and retinoid response in neuroblastoma cells2002
Professor Gareth Veal
Melanie Griffin
Annie Parry
Dr Juliet Hale
Professor Andrew Pearson
et al.
A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin2001
Professor Gareth Veal
Dr Cinera Dias
Annie Parry
Julie Errington
Dr Juliet Hale
et al.
Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy2001
Professor Gareth Veal
Julie Errington
Dr Chris Redfern
Professor Andrew Pearson
Professor Alan Boddy
et al.
Influence of retinoid isomerisation on the cellular activity of 13-cis retinoic acid in neuroblastoma2001
Professor Gareth Veal
Dr Cinera Dias
Professor Alan Boddy
Annie Parry
Dr Juliet Hale
et al.
In vitro/in vivo correlations of cisplatin-DNA adduct levels in leucocytes of children2000
Professor Gareth Veal
Professor Alan Boddy
Huw Thomas
Annie Parry
Professor Andrew Pearson
et al.
Real-time monitoring of carboplatin pharmacokinetics in paediatric patients receiving high dose chemotherapy1999
Professor Gareth Veal
Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro1998